ReviewJournal of molecular histology2026
The role of the AMPK/NLRP3 axis in osteoarthritic bone marrow lesions of the knee: from molecular mechanisms to clinical applications.
Review in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Knee osteoarthritis (KOA) is a major disabling disease worldwide, and the available treatments are largely limited to symptom control. The pathogenesis of bone marrow lesions (BMLs), a central driver of pain and progression, has not been fully elucidated. This review summarizes the core role of the AMP-activated protein kinase‒NOD-like receptor pyrin domain-containing protein 3 (AMPK‒NLRP3) signaling axis in BML pathogenesis and proposed a novel pathophysiological framework integrating metabolic dysfunction and the inflammatory response. Systematic literature analysis indicates that reduced AMPK activity may lead to overactivation of NLRP3 inflammasomes, forming a vicious cycle that promotes bone marrow lesion (BML) development. Based on these insights, we discusses potential therapeutic targets including AMPK activators, NLRP3 inhibitors, and autophagy enhancers, and proposes biomarker-based individualized therapeutic strategies. This review systematically elucidate the role of the AMPK/NLRP3 axis in KOA-related BMLs, integrats basic research and clinical observations, and provide a theoretical basis for novel therapeutic strategy development.
Indexed as
Identifiers
42043601What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.